Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and the novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, focus on improving lipid levels but ultimately aim to reduce the risk of CV events. Statins still dominate the market owing to their good risk-benefit profile and ability to reduce CVmorbidity and mortality. However, the evidence is not as strong for many of the nonstatin therapies. Using a longitudinal claims data analysis, we demonstrate how dyslipidemia is being treated in the United States and provide insight into what is driving current prescribing practices for newly diagnosed and recently treated patients.
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
KEY DRUGS COVERED
Repatha, Praluent, Crestor, Zetia, Vytorin, Lovaza, Vascepa, statins, fibrates, omega-3 fatty acid compounds
KEY ANALYSIS PROVIDED